1. Rahman, M.S. and K. Woollard, Atherosclerosis. Adv Exp Med Biol, 2017. 1003: p. 121-144.
2. Ference, B.A., et al., Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol, 2012. 60(25): p. 2631-9.
3. Holmes, M.V., et al., Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J, 2015. 36(9): p. 539-50.
4. Prospective Studies, C., et al., Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet, 2007. 370(9602): p. 1829-39.
5. Cholesterol Treatment Trialists, C., et al., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010. 376(9753): p. 1670-81.
6. Levinson, S.S., Non-High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History. Lab Med, 2020. 51(1): p. 14-23.
7. Ramjee, V., L.S. Sperling, and T.A. Jacobson, Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol, 2011. 58(5): p. 457-63.
8. Schmidt, K., et al., Structure, function, and genetics of lipoprotein (a). J Lipid Res, 2016. 57(8): p. 1339-59.
9. Oncel, R.C., et al., Relation of neutrophil-to-lymphocyte ratio with GRACE risk score to in-hospital cardiac events in patients with ST-segment elevated myocardial infarction. Clin Appl Thromb Hemost, 2015. 21(4): p. 383-8.
10. Balta, S., et al., The Relation Between Atherosclerosis and the Neutrophil-Lymphocyte Ratio. Clin Appl Thromb Hemost, 2016. 22(5): p. 405-11.
11. Zhang, C., et al., Lipid metabolism in inflammation-related diseases. Analyst, 2018. 143(19): p. 4526-4536.
12. Naka, K.K., et al., Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. J Clin Lipidol, 2018. 12(2): p. 338-347.
13. Zhao, L., et al., Variability in blood lipids affects the neutrophil to lymphocyte ratio in patients undergoing elective percutaneous coronary intervention: a retrospective study. Lipids Health Dis, 2020. 19(1): p. 124.
14. Marcovina, S.M., et al., Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. J Clin Lipidol, 2018. 12(1): p. 122-129 e2.
15. Pirro, M., et al., Lipoprotein(a) and inflammation: A dangerous duet leading to endothelial loss of integrity. Pharmacol Res, 2017. 119: p. 178-187.
16. Levine, G.N., et al., 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation, 2011. 124(23): p. 2574-609.
17. Rothwell, P.M., et al., Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet, 2010. 375(9718): p. 895-905.
18. Carr, S.S., et al., Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology, 2019. 51(2): p. 148-154.
19. Wu, M.F., et al., Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. Cardiovasc Drugs Ther, 2019. 33(6): p. 739-748.
20. Shoji, T., et al., Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. Clin J Am Soc Nephrol, 2011. 6(5): p. 1112-20.
21. Bittner, V., et al., Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation, 2002. 106(20): p. 2537-42.
22. Davidson, M.H., Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure? J Am Coll Cardiol, 2012. 60(25): p. 2616-7.
23. Clark, D., 3rd, et al., Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. Eur Heart J, 2018. 39(27): p. 2551-2558.
24. Zou, X., et al., Effects of serum lipid smoothness on the progression and vulnerability of atherosclerotic plaques in rabbits. PLoS One, 2014. 9(7): p. e93686.
25. Couture, P., et al., Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol, 1998. 18(6): p. 1007-12.
26. Heath, K.E., et al., The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis, 1999. 143(1): p. 41-54.
27. Kronenberg, F., Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. Cardiovasc Drugs Ther, 2016. 30(1): p. 87-100.
28. Hiltunen, T.P., et al., Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation, 1998. 97(11): p. 1079-86.
29. Enas, E.A., et al., Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J, 2019. 71(2): p. 99-112.